Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Amil Falls After UBS Drops ‘Buy’ Rating on Valuations

Don't Miss Out —
Follow us on:

July 16 (Bloomberg) -- Amil Participacoes SA fell the most in a month after UBS AG cut its rating on the health insurance provider to “neutral” from “buy,” citing its price relative to earnings following a two-month rally.

Amil, the Rio de Janeiro-based insurer that agreed to buy Medial Saude SA last year, fell 3.7 percent to 14.45 reais in Sao Paulo trading at 5 p.m. close. The stock surged 20 percent through yesterday from its May 18 low.

“We believe that the stock is already pricing in most of the benefits from a successful turnaround at Medial,” Gustavo Piras Oliveira, an analyst at UBS, wrote in a note to clients.

Amil fetches 44 times reported earnings, compared with a price-to-earnings ratio of 13 for the Bovespa stock index, according to Bloomberg data.

UBS prefers OdontoPrev SA, Brazil’s largest provider of dental-care plans, over Amil, according to the report.

OdontoPrev, which trades at 32 times profits, dropped 1.3 percent to 16.30 reais today.

To contact the reporter on this story: Alexander Ragir in Rio de Janeiro at aragir@bloomberg.net.

To contact the editor responsible for this story: David Papadopoulos at papadopoulos@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.